PA
FCX icon

PharVision Advisers’s Freeport-McMoran FCX Stock Holding History

PharVision Advisers’s Portfolio FCX Stock Details FCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,393
Closed -$223K – 294
2025
Q4 		$223K Sell
4,393
-4,214
-49% -$183K 0.11% 467
2025
Q3 		$338K Buy
+8,607
New +$373K 0.19% 159

Other funds holding FCX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PharVision Advisers's FCX Position: Q1 2026 in Review

PharVision Advisers sold out of Freeport-McMoran (FCX) in Q1 2026, closing a stake of 4,393 shares — an estimated $223K sold.

PharVision Advisers first reported a position in FCX in Q3 2025 and held it in 2 quarters. The position peaked at $338K in Q3 2025. 1,848 funds tracked by Wall St. Rank hold FCX as of Q1 2026.

  • PharVision Advisers reported no remaining Freeport-McMoran position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 4,393 Freeport-McMoran shares in Q1 2026, an estimated $223K.
  • PharVision Advisers first reported a position in Freeport-McMoran in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Freeport-McMoran position peaked at $338K in Q3 2025.
  • 1,848 funds tracked by Wall St. Rank held Freeport-McMoran as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.